Stephanie K Carnes1, Jonathan H Sheehan2, Christopher Aiken1. 1. Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center. 2. Department of Biochemistry and Center for Structural Biology, Vanderbilt University, Nashville, Tennessee, USA.
Abstract
PURPOSE OF REVIEW: To summarize recent advances in the discovery of chemical inhibitors targeting the HIV capsid and research on their mechanisms of action. RECENT FINDINGS: HIV infection is critically dependent on functions of the viral capsid. Numerous studies have reported the identification of a variety of compounds that bind to the capsid protein; some of these inhibit reverse transcription and nuclear entry, steps required for infection. Other capsid-targeting compounds appear to act by perturbing capsid assembly, resulting in noninfectious progeny virions. Inhibitors may bind to several different positions on the capsid protein, including sites in both protein domains. However, the antiviral activity of many reported capsid-targeting inhibitors has not been definitively linked to capsid binding. Until recently, the low-to-moderate potency of reported capsid-targeting inhibitors has precluded their further clinical development. In 2017, GS-CA1, a highly potent capsid inhibitor, was described that holds promise for clinical development. SUMMARY: Small molecules that bind to the viral capsid protein can be potent inhibitors of HIV infection. Capsid-targeting drugs are predicted to exhibit high barriers to viral resistance, and ongoing work in this area is contributing to an understanding of the molecular biology of HIV uncoating and maturation.
PURPOSE OF REVIEW: To summarize recent advances in the discovery of chemical inhibitors targeting the HIV capsid and research on their mechanisms of action. RECENT FINDINGS:HIV infection is critically dependent on functions of the viral capsid. Numerous studies have reported the identification of a variety of compounds that bind to the capsid protein; some of these inhibit reverse transcription and nuclear entry, steps required for infection. Other capsid-targeting compounds appear to act by perturbing capsid assembly, resulting in noninfectious progeny virions. Inhibitors may bind to several different positions on the capsid protein, including sites in both protein domains. However, the antiviral activity of many reported capsid-targeting inhibitors has not been definitively linked to capsid binding. Until recently, the low-to-moderate potency of reported capsid-targeting inhibitors has precluded their further clinical development. In 2017, GS-CA1, a highly potent capsid inhibitor, was described that holds promise for clinical development. SUMMARY: Small molecules that bind to the viral capsid protein can be potent inhibitors of HIV infection. Capsid-targeting drugs are predicted to exhibit high barriers to viral resistance, and ongoing work in this area is contributing to an understanding of the molecular biology of HIV uncoating and maturation.
Authors: Christopher T Lemke; Steve Titolo; Nathalie Goudreau; Anne Marie Faucher; Stephen W Mason; Pierre Bonneau Journal: Acta Crystallogr D Biol Crystallogr Date: 2013-05-15
Authors: Akash Bhattacharya; Steven L Alam; Thomas Fricke; Kaneil Zadrozny; Jaroslaw Sedzicki; Alexander B Taylor; Borries Demeler; Owen Pornillos; Barbie K Ganser-Pornillos; Felipe Diaz-Griffero; Dmitri N Ivanov; Mark Yeager Journal: Proc Natl Acad Sci U S A Date: 2014-12-17 Impact factor: 11.205
Authors: Akatsuki Saito; Damien Ferhadian; Gregory A Sowd; Erik Serrao; Jiong Shi; Upul D Halambage; Samantha Teng; Juan Soto; Mohammad Adnan Siddiqui; Alan N Engelman; Christopher Aiken; Masahiro Yamashita Journal: J Virol Date: 2016-05-27 Impact factor: 5.103
Authors: Ke Peng; Walter Muranyi; Bärbel Glass; Vibor Laketa; Stephen R Yant; Luong Tsai; Tomas Cihlar; Barbara Müller; Hans-Georg Kräusslich Journal: Elife Date: 2014-12-17 Impact factor: 8.140
Authors: Jenna E Eschbach; Jennifer L Elliott; Wen Li; Kaneil K Zadrozny; Keanu Davis; Shawn J Mohammed; Dana Q Lawson; Owen Pornillos; Alan N Engelman; Sebla B Kutluay Journal: J Virol Date: 2020-12-22 Impact factor: 5.103
Authors: Lei Wang; Mary C Casey; Sanjeev Kumar V Vernekar; Rajkumar Lalji Sahani; Jayakanth Kankanala; Karen A Kirby; Haijuan Du; Atsuko Hachiya; Huanchun Zhang; Philip R Tedbury; Jiashu Xie; Stefan G Sarafianos; Zhengqiang Wang Journal: Eur J Med Chem Date: 2020-07-19 Impact factor: 6.514
Authors: John O Link; Martin S Rhee; Winston C Tse; Jim Zheng; John R Somoza; William Rowe; Rebecca Begley; Anna Chiu; Andrew Mulato; Derek Hansen; Eric Singer; Luong K Tsai; Rujuta A Bam; Chien-Hung Chou; Eda Canales; Gediminas Brizgys; Jennifer R Zhang; Jiayao Li; Michael Graupe; Philip Morganelli; Qi Liu; Qiaoyin Wu; Randall L Halcomb; Roland D Saito; Scott D Schroeder; Scott E Lazerwith; Steven Bondy; Debi Jin; Magdeleine Hung; Nikolai Novikov; Xiaohong Liu; Armando G Villaseñor; Carina E Cannizzaro; Eric Y Hu; Robert L Anderson; Todd C Appleby; Bing Lu; Judy Mwangi; Albert Liclican; Anita Niedziela-Majka; Giuseppe A Papalia; Melanie H Wong; Stephanie A Leavitt; Yili Xu; David Koditek; George J Stepan; Helen Yu; Nikos Pagratis; Sheila Clancy; Shekeba Ahmadyar; Terrence Z Cai; Scott Sellers; Scott A Wolckenhauer; John Ling; Christian Callebaut; Nicolas Margot; Renee R Ram; Ya-Pei Liu; Rob Hyland; Gary I Sinclair; Peter J Ruane; Gordon E Crofoot; Cheryl K McDonald; Diana M Brainard; Latesh Lad; Swami Swaminathan; Wesley I Sundquist; Roman Sakowicz; Anne E Chester; William E Lee; Eric S Daar; Stephen R Yant; Tomas Cihlar Journal: Nature Date: 2020-07-01 Impact factor: 49.962
Authors: Qinfang Sun; Ronald M Levy; Karen A Kirby; Zhengqiang Wang; Stefan G Sarafianos; Nanjie Deng Journal: Viruses Date: 2021-05-15 Impact factor: 5.048